Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model-Reference-Cited by-同舟云学术

Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model

Published:2013-03-22 Issue:5 Volume:52 Page:359-371
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Abduljalil Khaled,Lazar Simone,Natanzon Michael,Wu Weidong,Zadoyan Gregor,Steffens Benedict,Kohl Victoria,Mörike Klaus,Tomalik-Scharte Dorota,Stingl Julia,Schwab Matthias,Harenberg Job,Gleiter Christoph,Fuhr Uwe

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-013-0043-z.pdf

Reference44 articles.

1. Bourgain R, Wright IS. Marcumar, a new anticoagulant. Revue d’hematologie. 1955;10(2):387–9 (discussion 412–22).

2. Trenk D, Althen H, Jahnchen E, et al. Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol. 1987;33(1):49–54.

3. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114[Suppl 5]:445S–69S.

4. Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47(9):565–94.

5. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007;81(2):185–93.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms;Frontiers in Pharmacology;2020-01-28

2. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications;The Pharmacogenomics Journal;2019-10-15

3. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension;Annals of Hepatology;2014-11